|
1
|
Enzinger FM: Epitheloid sarcoma. A sarcoma
simulating a granuloma or a carcinoma. Cancer. 26:1029–1041.
1970.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Spillane AJ, Thomas JM and Fisher C:
Epithelioid sarcoma: The clinicopathological complexities of this
rare soft tissue sarcoma. Ann Surg Oncol. 7:218–225.
2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
de Visscher SA, van Ginkel RJ, Wobbes T,
Veth RP, Ten Heuvel SE, Suurmeijer AJ and Hoekstra HJ: Epithelioid
sarcoma: Still an only surgically curable disease. Cancer.
107:606–612. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Frezza AM, Jones RL, Lo Vullo S, Asano N,
Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, et
al: Anthracycline, gemcitabine, and pazopanib in epithelioid
sarcoma: A multi-institutional case series. JAMA Oncol.
4(e180219)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gounder MM, Merriam P, Ratan R, Patel SR,
Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH,
Whalen J, et al: Real-world outcomes of patients with locally
advanced or metastatic epithelioid sarcoma. Cancer. 127:1311–1317.
2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Touati N, Schöffski P, Litière S, Judson
I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T,
Blay JY, et al: European organisation for research and treatment of
cancer soft tissue and bone sarcoma group experience with
advanced/metastatic epithelioid sarcoma patients treated in
prospective trials: Clinical profile and response to systemic
therapy. Clin Oncol (R Coll Radiol). 30:448–454. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gounder M, Schöffski P, Jones RL, Agulnik
M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, et
al: Tazemetostat in advanced epithelioid sarcoma with loss of
INI1/SMARCB1: An international, open-label, phase 2 basket study.
Lancet Oncol. 21:1423–1432. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Guillou L, Wadden C, Coindre JM, Krausz T
and Fletcher CD: ‘Proximal-type’ epithelioid sarcoma, a distinctive
aggressive neoplasm showing rhabdoid features. Clinicopathologic,
immunohistochemical, and ultrastructural study of a series. Am J
Surg Pathol. 21:130–146. 1997.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Alikhan MB, Pease G, Watkin W, Grogan R,
Krausz T and Antic T: Primary epithelioid sarcoma of the kidney and
adrenal gland: Report of 2 cases with immunohistochemical and
molecular cytogenetic studies. Hum Pathol. 61:158–163.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Huang X, Nayar R and Zhou H: Primary
adrenal gland epithelioid sarcoma: A case report and literature
review. Diagn Cytopathol. 47:918–921. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Martinez VP, Nicholson M and Patel T:
Abnormal Adrenal mass presents as proximal epithelioid sarcoma.
Case Rep Urol. 2020(8864218)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Seymour L, Bogaerts J, Perrone A, Ford R,
Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et
al: iRECIST: Guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 18:e143–e152.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hornick JL, Dal Cin P and Fletcher CD:
Loss of INI1 expression is characteristic of both conventional and
proximal-type epithelioid sarcoma. Am J Surg Pathol. 33:542–550.
2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jones RL, Constantinidou A, Olmos D, Thway
K, Fisher C, Al-Muderis O, Scurr M and Judson IR: Role of
palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin
Oncol. 35:351–357. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kim C, Yoo KH, Kim MH, Chon HJ, Lee SI,
Lee HJ, Koh S, Lee HY, Lee HR, Kim KS, et al: Different subtypes of
epithelioid sarcoma and their clinical implication: Long-term
multi-institutional experience with a rare sarcoma. APMIS.
125:223–229. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Italiano A, Bellera C and D'Angelo S:
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: A pooled
analysis of phase II trials. J Hematol Oncol. 13(55)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
D'Angelo SP, Mahoney MR, Van Tine BA,
Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap
WD, Schwartz GK and Streicher H: Nivolumab with or without
ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two
open-label, non-comparative, randomised, phase 2 trials. Lancet
Oncol. 19:416–426. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tawbi HA, Burgess M, Bolejack V, Van Tine
BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA,
et al: Pembrolizumab in advanced soft-tissue sarcoma and bone
sarcoma (SARC028): A multicentre, two-cohort, single-arm,
open-label, phase 2 trial. Lancet Oncol. 18:1493–1501.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Toulmonde M, Penel N, Adam J, Chevreau C,
Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S,
Grellety T, et al: Use of PD-1, targeting macrophage infiltration,
and IDO pathway activation in sarcomas: A phase 2 clinical trial.
JAMA Oncol. 4:93–97. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cancer Genome Atlas Research Network.
Electronic address: simpleelizabeth.demicco@sinaihealthsystem.ca;
Cancer Genome Atlas Research Network. Comprehensive and integrated
genomic characterization of adult soft tissue sarcomas. Cell.
171:950–965.e28. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
He M, Abro B, Kaushal M, Chen L, Chen T,
Gondim M, Yan W, Neidich J, Dehner LP and Pfeifer JD: Tumor
mutation burden and checkpoint immunotherapy markers in primary and
metastatic synovial sarcoma. Hum Pathol. 100:15–23. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Paoluzzi L, Cacavio A, Ghesani M,
Karambelkar A, Rapkiewicz A, Weber J and Rosen G: Response to
anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin
Sarcoma Res. 6(24)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pecora A, Halpern S, Weber M, Paleoudis
EG, Panush D, Patterson F and Toretsky J: Rapid and Complete
response to combination anti-CTLA-4 and Anti-PD-1 checkpoint
inhibitor therapy in a patient with stage IV refractory end-stage
epithelioid sarcoma: A case report. J Immunother. 43:286–290.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li C, Bhatti SA and Ying J: Immune
checkpoint inhibitors-associated cardiotoxicity. Cancers (Basel).
14(1145)2022.PubMed/NCBI View Article : Google Scholar
|
